The Independent Data Monitoring Committee (IDMC) Recommends Continuation of the Alenura Clinical Trial Following Interim Assessment. Read full Press Release.
December 14, 2024, New Brunswick, NJ – Vaneltix Pharma, Inc. (“Vaneltix” or “the Company”), a specialty pharmaceutical company focused on the development of solutions for the six million people with...
On Tuesday, February 21st 2023, Bound Brook, NJ – Vaneltix Pharma, Inc. (Formerly Urigen Pharmaceuticals, Inc.; “Vaneltix” or “the Company”), a specialty pharmaceutical company focused on the development solutions for...
On Thursday, December 16, Vaneltix entered into a Joint Development Agreement with Hyloris Pharmaceuticals NV, a Belgian pharmaceuticals company (“Hyloris”) with respect to Vaneltix’s Alenura™ product candidate. Under the Joint...
Vaneltix announces the results of the 2020 Stockholder Offering and Bridge Loan Conversion: The company raised additional proceeds of $900,000 and all the Bridge Loans were converted into Common Stock...
